Yuko Shiroyama

416 total citations
26 papers, 307 citations indexed

About

Yuko Shiroyama is a scholar working on Reproductive Medicine, Surgery and Obstetrics and Gynecology. According to data from OpenAlex, Yuko Shiroyama has authored 26 papers receiving a total of 307 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Reproductive Medicine, 6 papers in Surgery and 6 papers in Obstetrics and Gynecology. Recurrent topics in Yuko Shiroyama's work include Ovarian cancer diagnosis and treatment (10 papers), Endometrial and Cervical Cancer Treatments (6 papers) and Cervical Cancer and HPV Research (4 papers). Yuko Shiroyama is often cited by papers focused on Ovarian cancer diagnosis and treatment (10 papers), Endometrial and Cervical Cancer Treatments (6 papers) and Cervical Cancer and HPV Research (4 papers). Yuko Shiroyama collaborates with scholars based in Japan and United States. Yuko Shiroyama's co-authors include Koso Ohama, Kazushi Shigemasa, Nobutaka Nagai, Takashi Yokoyama, Osamu Katoh, Shoji Mihara, Kazuhiro Takehara, Lijun Gu, Takayoshi Nogawa and Yasuko Yamamoto and has published in prestigious journals such as Journal of Clinical Oncology, BMC Cancer and International Journal of Oncology.

In The Last Decade

Yuko Shiroyama

23 papers receiving 302 citations

Peers

Yuko Shiroyama
Yuko Shiroyama
Citations per year, relative to Yuko Shiroyama Yuko Shiroyama (= 1×) peers Chenglei Gu

Countries citing papers authored by Yuko Shiroyama

Since Specialization
Citations

This map shows the geographic impact of Yuko Shiroyama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuko Shiroyama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuko Shiroyama more than expected).

Fields of papers citing papers by Yuko Shiroyama

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuko Shiroyama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuko Shiroyama. The network helps show where Yuko Shiroyama may publish in the future.

Co-authorship network of co-authors of Yuko Shiroyama

This figure shows the co-authorship network connecting the top 25 collaborators of Yuko Shiroyama. A scholar is included among the top collaborators of Yuko Shiroyama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuko Shiroyama. Yuko Shiroyama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nakamura, Keiichiro, Hirofumi Matsuoka, Hiroko Nakamura, et al.. (2023). Efficacy and safety of olaparib, olaparib plus bevacizumab and niraparib maintenance treatment in Japanese patients with platinum-sensitive advanced ovarian cancer. Japanese Journal of Clinical Oncology. 54(1). 31–37. 3 indexed citations
2.
Fujimoto, Etsuko, et al.. (2018). Long-term outcomes of postoperative taxane/platinum chemotherapy for early stage cervical cancer: a retrospective study. International Journal of Clinical Oncology. 23(4). 715–725. 3 indexed citations
3.
Takehara, Kazuhiro, Etsuko Fujimoto, Yuko Shiroyama, et al.. (2018). Lynch syndrome-associated endometrial carcinoma with MLH1 germline mutation and MLH1 promoter hypermethylation: a case report and literature review. BMC Cancer. 18(1). 576–576. 30 indexed citations
4.
Matsuoka, Naoki, et al.. (2017). [Safety and Efficacy of Cisplatin Treatment after Carboplatin Hypersensitivity Reactions in Gynecologic Malignancies].. PubMed. 44(13). 2091–2095.
5.
Shiroyama, Yuko, et al.. (2016). [Outcomes of Tertiary Debulking Surgery(TDS)for Re-Recurrent Ovarian Cancer].. PubMed. 43(3). 357–60.
6.
Yamamoto, Yasuko, Kazuhiro Takehara, Yuko Shiroyama, et al.. (2015). A case of ependymoma arising from the peritoneum. International Cancer Conference Journal. 5(3). 121–125. 1 indexed citations
7.
Kojima, Atsumi, Norihiro Teramoto, Yuko Shiroyama, et al.. (2015). Type C2 radical hysterectomy may improve outcomes of locally advanced mucinous adenocarcinoma of the uterine cervix. International Journal of Clinical Oncology. 21(4). 723–729. 3 indexed citations
8.
Takehara, Kazuhiro, et al.. (2015). The usefulness of 18F-FDG-PET/CT in discriminating benign from malignant ovarian teratomas. International Journal of Clinical Oncology. 20(5). 960–966. 10 indexed citations
9.
Takehara, Kazuhiro, Atsumi Kojima, Yasuko Yamamoto, et al.. (2014). Maximum Standardized Uptake Value of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Is a Prognostic Factor in Ovarian Clear Cell Adenocarcinoma. International Journal of Gynecological Cancer. 24(7). 1190–1194. 34 indexed citations
10.
Matsumoto, Koji, Nobuo Yaegashi, Takashi Iwata, et al.. (2014). Monitoring the Impact of a National HPV Vaccination Program in Japan (MINT Study): Rationale, Design and Methods. Japanese Journal of Clinical Oncology. 44(10). 1000–1003. 8 indexed citations
11.
Takehara, Kazuhiro, Atsumi Kojima, Yuko Shiroyama, et al.. (2014). SUV max of FDG-PET/CT as a prognostic factor in ovarian clear cell adenocarcinoma.. Journal of Clinical Oncology. 32(15_suppl). e16509–e16509. 2 indexed citations
12.
Ohsumi, Shozo, Mina Takahashi, Daisuke Takabatake, et al.. (2013). Our System of Management of Hereditary Breast/Ovarian Cancer (HBOC). Nihon Nyugan Kenshin Gakkaishi (Journal of Japan Association of Breast Cancer Screening). 22(2). 187–192. 1 indexed citations
13.
Hiura, Masamichi, et al.. (2010). Long-Term Survival in Patients With Para-Aortic Lymph Node Metastasis With Systematic Retroperitoneal Lymphadenectomy Followed by Adjuvant Chemotherapy in Endometrial Carcinoma. International Journal of Gynecological Cancer. 20(6). 1000–1005. 16 indexed citations
14.
Nagai, Nobutaka, et al.. (2004). Human papillomavirus DNA status after loop excision for cervical intraepithelial neoplasia grade III - A prospective study. International Journal of Molecular Medicine. 13(4). 589–93. 12 indexed citations
15.
Nagai, Nobutaka, Eiji Hirata, T. Kusuda, et al.. (2003). Overexpression of cyclooxygenase-2 protein and its relationship to apoptosis in cervical carcinoma treated with neoadjuvant chemotherapy. International Journal of Molecular Medicine. 12(5). 709–14. 11 indexed citations
16.
Shigemasa, Kazushi, et al.. (2003). Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas. International Journal of Oncology. 22(1). 99–105. 48 indexed citations
17.
Shigemasa, Kazushi, Osamu Katoh, Yuko Shiroyama, et al.. (2002). Increased MCL–1 Expression Is Associated with Poor Prognosis in Ovarian Carcinomas. Japanese Journal of Cancer Research. 93(5). 542–550. 71 indexed citations
18.
Shigemasa, Kazushi, Yuko Shiroyama, Tatsuya Sawasaki, et al.. (2001). Underexpression of cyclin-dependent kinase inhibitor p27 is associated with poor prognosis in serous ovarian carcinomas. International Journal of Oncology. 18(5). 953–8. 19 indexed citations
19.
Shigemasa, Kazushi, Yuko Shiroyama, T. Kusuda, et al.. (2001). Cyclin E mRNA Overexpression in Epithelial Ovarian Cancers: Inverse Correlation with p53 Protein Accumulation. Journal of the Society for Gynecologic Investigation. 8(3). 179–185. 15 indexed citations
20.
Higashino, Takeshi, Junichi Yoshii, Yuko Shiroyama, et al.. (1997). [A case of multiple cholesterol polyps of the gallbladder with intermittent jaundice of frequent occurrence].. PubMed. 94(5). 376–80. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026